Aldeyra Therapeutics, Inc.
reproxalap
dry eye disease
Resolved
157days ago
FDA decision · Mar 17, 2026
What's at stake
An FDA complete response letter on reproxalap for dry eye disease is in focus around Mar 17, 2026.
Primary source
· SEC 8-K
verified 2mo ago
“Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease”